Literature DB >> 33277428

Multiple, objectively measured sleep dimensions including hypoxic burden and chronic kidney disease: findings from the Multi-Ethnic Study of Atherosclerosis.

Chandra L Jackson1,2, Chizoba Umesi3,4, Symielle A Gaston3, Ali Azarbarzin5,6, Joseph Lunyera7, John A McGrath8, W Braxton Jackson Ii8, Clarissa J Diamantidis4,7, Ebony Boulware4,7, Pamela L Lutsey9, Susan Redline5,6,10.   

Abstract

BACKGROUND: Poor sleep may contribute to chronic kidney disease (CKD) through several pathways, including hypoxia-induced systemic and intraglomerular pressure, inflammation, oxidative stress and endothelial dysfunction. However, few studies have investigated the association between multiple objectively measured sleep dimensions and CKD.
METHODS: We investigated the cross-sectional association between sleep dimensions and CKD among 1895 Multi-Ethnic Study of Atherosclerosis Sleep Ancillary Study participants who completed in-home polysomnography, wrist actigraphy and a sleep questionnaire. Using Poisson regression models with robust variance, we estimated separate prevalence ratios (PR) and 95% CIs for moderate-to-severe CKD (glomerular filtration rate <60 mL/min/1.73 m2 or albuminuria >30 mg/g) among participants according to multiple sleep dimensions, including very short (≤5 hours) sleep, Apnoea-Hypopnoea Index and sleep apnoea-specific hypoxic burden (SASHB) (total area under the respiratory event-related desaturation curve divided by total sleep duration, %min/hour)). Regression models were adjusted for sociodemographic characteristics, health behaviours and clinical characteristics.
RESULTS: Of the 1895 participants, mean age was 68.2±9.1 years, 54% were women, 37% were white, 28% black, 24% Hispanic/Latino and 11% Asian. Several sleep metrics were associated with higher adjusted PR of moderate-to-severe CKD: very short versus recommended sleep duration (PR=1.40, 95% CI 1.06 to 1.83); SASHB (Box-Cox transformed SASHB: PR=1.06, 95% CI 1.02 to 1.12); and for participants in the highest quintile of SASHB plus sleep apnoea: PR=1.28, 95% CI 1.01 to 1.63.
CONCLUSIONS: Sleep apnoea associated hypoxia and very short sleep, likely representing independent biological mechanisms, were associated with a higher moderate-to-severe CKD prevalence, which highlights the potential role for novel interventions. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  oxidative stress; sleep apnoea

Year:  2020        PMID: 33277428      PMCID: PMC8175452          DOI: 10.1136/thoraxjnl-2020-214713

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  46 in total

1.  Association of short sleep duration and rapid decline in renal function.

Authors:  Ciaran J McMullan; Gary C Curhan; John P Forman
Journal:  Kidney Int       Date:  2016-03-25       Impact factor: 10.612

Review 2.  Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease?

Authors:  Rupal Mehta; Paul E Drawz
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

3.  Association of nocturnal hypoxemia with progression of CKD.

Authors:  Yusuke Sakaguchi; Tsuguru Hatta; Terumasa Hayashi; Tatsuya Shoji; Akira Suzuki; Kodo Tomida; Noriyuki Okada; Hiromi Rakugi; Yoshitaka Isaka; Yoshiharu Tsubakihara
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-06       Impact factor: 8.237

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 5.  Obstructive sleep apnea and kidney disease: is there any direct link?

Authors:  Aibek E Mirrakhimov
Journal:  Sleep Breath       Date:  2011-12-15       Impact factor: 2.816

Review 6.  A review of evidence for the link between sleep duration and hypertension.

Authors:  James E Gangwisch
Journal:  Am J Hypertens       Date:  2014-04-28       Impact factor: 2.689

Review 7.  Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment.

Authors:  Jutta Neumann; Gerry Ligtenberg; Inge I Klein; Hein A Koomans; Peter J Blankestijn
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

8.  Daytime sleepiness in stable hemodialysis patients.

Authors:  Kathy P Parker; Donald L Bliwise; James L Bailey; David B Rye
Journal:  Am J Kidney Dis       Date:  2003-02       Impact factor: 8.860

9.  Meta-analysis of short sleep duration and obesity in children and adults.

Authors:  Francesco P Cappuccio; Frances M Taggart; Ngianga-Bakwin Kandala; Andrew Currie; Ed Peile; Saverio Stranges; Michelle A Miller
Journal:  Sleep       Date:  2008-05       Impact factor: 5.849

10.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

View more
  3 in total

1.  Adherence to a Healthy Sleep Pattern and Risk of Chronic Kidney Disease: The UK Biobank Study.

Authors:  Tingting Geng; Xiang Li; Hao Ma; Yoriko Heianza; Lu Qi
Journal:  Mayo Clin Proc       Date:  2022-01       Impact factor: 7.616

Review 2.  The Need for Social and Environmental Determinants of Health Research to Understand and Intervene on Racial/Ethnic Disparities in Obstructive Sleep Apnea.

Authors:  Dayna A Johnson; Chidinma Ohanele; Carmela Alcántara; Chandra L Jackson
Journal:  Clin Chest Med       Date:  2022-06       Impact factor: 4.967

3.  Sleep Apnea-Specific Hypoxic Burden and Not the Sleepy Phenotype as a Novel Measure of Cardiovascular and Mortality Risk in a Clinical Cohort.

Authors:  Reena Mehra; Ali Azarbarzin
Journal:  Am J Respir Crit Care Med       Date:  2022-01-01       Impact factor: 30.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.